These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 31381552

  • 1. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul 29; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract] [Full Text] [Related]

  • 2. Siponimod (Mayzent)--a new drug for multiple sclerosis.
    Med Lett Drugs Ther; 2019 May 06; 61(1571):70-72. PubMed ID: 31169805
    [No Abstract] [Full Text] [Related]

  • 3. Drugs for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Mar 22; 63(1620):42-48. PubMed ID: 33976089
    [No Abstract] [Full Text] [Related]

  • 4. Ozanimod (Zeposia) for multiple sclerosis.
    Med Lett Drugs Ther; 2020 Aug 24; 62(1605):132-134. PubMed ID: 32970043
    [No Abstract] [Full Text] [Related]

  • 5. Ublituximab (Briumvi) for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 2023 Mar 06; 65(1671):36-38. PubMed ID: 36877282
    [No Abstract] [Full Text] [Related]

  • 6. Ponesimod (Ponvory) for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Aug 09; 63(1630):123-125. PubMed ID: 34550110
    [No Abstract] [Full Text] [Related]

  • 7.
    ; 2012 Aug 09. PubMed ID: 31643690
    [Abstract] [Full Text] [Related]

  • 8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.
    Cochrane Database Syst Rev; 2017 Apr 25; 4(4):CD012200. PubMed ID: 28440858
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
    Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, Alroughani R, Eichau Madueño S, Boz C, van der Walt A, Butzkueven H, Buzzard K, Skibina O, Foschi M, Grand'Maison F, John N, Grammond P, Terzi M, Prévost J, Barnett M, Laureys G, Van Hijfte L, Luis Sanchez-Menoyo J, Blanco Y, Oh J, McCombe P, Ramo Tello C, Soysal A, Prat A, Duquette P, Yamout BI, Khoury S, van Pesch V, Macdonell R, José Sá M, Slee M, Kuhle J, Maimone D, Spitaleri D, Willekens B, Asmi AA, Tallantyre E, Robertson NP, Coles A, L Brown JW, Kalincik T.
    Mult Scler; 2024 Aug 25; 30(9):1163-1175. PubMed ID: 39087208
    [Abstract] [Full Text] [Related]

  • 10. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P, Martinelli V, Pfleger C, Rieckmann P, Alonso-Magdalena L, Galazka A, Dangond F, Phillips L.
    Clin Ther; 2019 Feb 25; 41(2):249-260.e18. PubMed ID: 30846120
    [Abstract] [Full Text] [Related]

  • 11. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
    Mankinen P, Lundström T, Soini E, Sumelahti ML, Ruutiainen J, Niskala U, Järvinen E.
    Adv Ther; 2020 Feb 25; 37(2):800-818. PubMed ID: 31873868
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul 25; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 13. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
    Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Der Walt AV, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Morgado YB, Spitaleri D, Pesch VV, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H, MSBase Study Group.
    Neurodegener Dis Manag; 2023 Aug 25; 13(4):215-221. PubMed ID: 37287269
    [Abstract] [Full Text] [Related]

  • 14. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Śladowska K, Kawalec P, Holko P, Osiecka O.
    Neurol Sci; 2022 Sep 25; 43(9):5479-5500. PubMed ID: 35713731
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B, Guerreiro R, Costa J, Miguel LS.
    J Med Econ; 2020 May 25; 23(5):484-491. PubMed ID: 31951777
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis.
    Paolicelli D, Manni A, Iaffaldano A, Trojano M.
    CNS Drugs; 2020 Jan 25; 34(1):65-92. PubMed ID: 31898276
    [Abstract] [Full Text] [Related]

  • 17. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B.
    Am J Manag Care; 2013 Nov 25; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [Abstract] [Full Text] [Related]

  • 18. [Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis].
    Boyko AN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022 Nov 25; 122(7. Vyp. 2):73-77. PubMed ID: 35912560
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.